Colruyt Group N.V. : A new test of the support level
Entry price | Target | Stop-loss | Potential |
---|
€0 |
€56 |
€44 |
+∞% |
---|
Colruyt NV have been fluctuating horizontally for several weeks. As the share price returns to the lower bound of the accumulation zone, it yoffers a good timing for investors to open new long positions.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The company has solid fundamentals for a short-term investment strategy.
Strengths● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● Historically, the company has been releasing figures that are above expectations.
● The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● The stock is in a well-established, long-term rising trend above the technical support level at 48.3 EUR
Weaknesses● Most analysts recommend that the stock should be sold or reduced.
● The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.